{
    "nctId": "NCT00288002",
    "briefTitle": "Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer",
    "officialTitle": "A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1500,
    "primaryOutcomeMeasure": "Pathologic complete response",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed unilateral or bilateral primary breast cancer\n\n  * Meets 1 of the following staging criteria:\n\n    * Clinical stage T4 or T3 disease\n    * Clinical stage T1 and pathologic stage N+ by sentinel lymph node biopsy OR clinical stage T2, N+ disease AND estrogen receptor (ER) or progesterone receptor (PR) positive tumor\n    * ER and PR negative tumor (T1-4, N0-3, M0)\n* Disease confirmed by core biopsy\n\n  * No fine-needle aspiration or incisional biopsy\n* Bidimensionally measurable disease\\*\n\n  * Tumor lesion palpable and measures \u2265 2 cm OR tumor lesion \u2265 1 cm in maximum diameter by sonography\n\n    * For inflammatory disease, extent of inflammation can be used as measurable lesion NOTE: \\*In patients with multifocal or multicentric breast cancer, the largest lesion should be measured\n* Candidate for adjuvant chemotherapy\n\n  * No low- or moderate-risk patients who are doubtful candidates for adjuvant chemotherapy and do not fulfill the staging criteria\n* Known HER-2/neu status by core biopsy\n\n  * HER-2/neu positive tumor is defined as +3 by immunohistochemistry \\[IHC\\] OR positive by fluorescence in situ hybridization (FISH)\n* No evidence of distant metastasis\n* Hormone receptor status:\n\n  * ER- or PR-positive tumor OR ER- and PR-negative tumor\n\nPATIENT CHARACTERISTICS:\n\n* No male patients\n* Menopausal status not specified\n* Karnofsky performance status 80-100%\n* Life expectancy \u2265 10 years (disregarding diagnosis of cancer)\n* Normal cardiac function confirmed by ECG\n* LVEF \u2265 55% by cardiac ultrasound\n* Neutrophil count \u2265 2,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 10 g/dL\n* Bilirubin normal\n* AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n* Alkaline phosphatase (AP) \u2264 5 times ULN OR\n* AP \u2264 2.5 times ULN AND AST and/or ALT \u2264 1.5 times ULN\n* Creatinine \u2264 2 mg/dL\n* Creatinine clearance \u2265 50 mL/min\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective nonhormonal contraception\n* No motor or sensory neuropathy \u2265 grade 2\n* No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer\n* No New York Heart Association class II-IV congestive heart failure\n* No coronary artery disease\n* No history of myocardial infarction\n* No uncontrolled arterial hypertension (i.e., blood pressure \u2265 160/90 mm Hg despite antihypertensive therapy)\n* No rhythm abnormalities requiring permanent therapy\n* No history of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would preclude giving informed consent\n* No active infection\n* No active peptic ulcer\n* No unstable diabetes mellitus or insulin-dependent type II diabetes mellitus\n* No other serious illness or medical condition\n* No known hypersensitivity reaction to investigational compounds or incorporated substances\n* No definite contraindications for the use of corticosteroids\n* No known dihydropyrimidine dehydrogenase deficiency\n* Must be fit for anthracycline/taxane-containing chemotherapy\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy for any malignancy\n* No prior radiation therapy for breast cancer\n* No concurrent bisphosphonates during chemotherapy\n\n  * Bisphosphonates allowed postoperatively\n* No chronic treatment with corticosteroids unless it is initiated \\> 6 months prior to study entry and is given at low doses (\u2264 20 mg methylprednisolone or equivalent)\n* No concurrent amifostine during chemotherapy\n* No concurrent cardioprotectors (e.g., dexrazoxane) during chemotherapy\n* No concurrent sex hormone therapy\n* No concurrent virostatic agents (e.g., sorivudine or brivudine)\n* No concurrent aminoglycosides\n* No other concurrent experimental drugs or anticancer therapy\n* At least 30 days since prior participation in another clinical trial with any investigational (not marketed) drug",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}